Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: There are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD). Aims: To conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125). Method: Patients (n= 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent. Results: There was a significant effect of baclofen (composite groups) on time to lapse (χ 2= 6.44,P<0.05, Cohen's d= 0.56) and relapse (χ 2= 4.62,P<0.05,d= 0.52). A significant treatment effect of baclofen was observed for percentage days abstinent (placebo 43%, baclofen 30 mg 69%, baclofen 75 mg 65%;P<0.05). There was one serious adverse event (overdose) directly related to medication (75 mg). Conclusions: Baclofen may be an effective treatment option for patients with ALD. However, given the profile of adverse events, the role for this medication might be best limited to specialist services. Declaration of interest: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“28 In addition, trained interviewers conducted a structured psychiatric diagnostic interview using the Mini-International Neuropsychiatric Interview (MINI).”
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
The model for end-stage liver disease (MELD)
Kamath, P. S., & Kim, R. W. (2007) · Hepatology · doi:10.1002/hep.21563 · Cited by 1,674
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852
Worldwide mortality from cirrhosis: An update to 2002
Bosetti, C., Levi, F., Lucchini, F., Zatonski, W. A., Negri, E., & La Vecchia, C. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.025 · Cited by 230
Missing Data in Alcohol Clinical Trials: A Comparison of Methods
Hallgren, K. A., & Witkiewitz, K. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12205 · Cited by 176
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence
Gupta, M., Verma, P., Rastogi, R., Arora, S., & Elwadhi, D. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1240797 · Cited by 26
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Some of these appear to have particular promise in specific cases, such as varenicline’s use for nicotine and alcohol co-users [147], baclofen for individuals with liver disease [93], and aripiprazole for more impulsive individuals [156].”
BackgroundThe Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Self-citationGarbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68
Management of alcohol use disorder in patients with chronic liver disease
Mellinger, J. L., Fernandez, A. C., & Winder, G. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000145 · Cited by 52
“[65] A more recent randomized trial, the BacALD trial, examined the effects of baclofen at either 10 mg 3 times daily or 25 mg 3 times daily for 12 weeks in a cohort of patients with and without ALD.[66] Abstinence rates were similar between the baclofen 30- and 75-mg groups (21% and 23% respectively, p = 0.”
BackgroundIdentification of a G-Protein-Independent Activator of GIRK Channels
Zhao, Y., Ung, P. M.-U., Zahoránszky-Kőhalmi, G., Zakharov, A. V., Martinez, N. J., Simeonov, A., Glaaser, I. W., Rai, G., Schlessinger, A., Marugan, J. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107770 · Cited by 39
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“To ensure an efficient and safe administration more clinical studies are needed to specify indications and patient selection, as well as to refine individual titration of baclofen dose (Morley et al., 2018; Rose and Jones, 2018; Garbutt et al., 2021).”
BackgroundCrunelle, C. L., Jegham, S., Vanderbruggen, N., & Matthys, F. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad050 · Cited by 5
Metadata
- Authors
- Morley, K. C., Baillie, A., Fraser, I., Furneaux-Bate, A., Dore, G., Roberts, M., Abdalla, A., Phung, N., & Haber, P. S.
- Venue
- The British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2018-05-02
- Volume
- 212
- Issue
- 6
- Pages
- 362-369
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2802163639
- Cited by
- 119
- References
- 8
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.